neratinib
Overview
Neratinib is an irreversible pan-ErbB (EGFR/HER2/HER4) tyrosine kinase inhibitor with FDA approval for extended adjuvant treatment of HER2-positive early breast cancer. It is under investigation in HER2-mutant/amplified cancers of other histologies.
Evidence in the corpus
- In 177 cervical cancers profiled by MSK-IMPACT, neratinib demonstrated 25% ORR and 7.0-month median PFS in HER2-mutant cervical cancer; ERBB2 is altered in 28% of unusual endocervical adenocarcinoma (UEA) subtype and 12% overall, making it a likely important therapeutic target in cervical cancer PMID:37643132.
- Bevacizumab was referenced as a prior therapy in the cervical cancer cohort; neratinib represents a HER2-directed alternative with emerging evidence PMID:37643132.
- HER2 resistance context in CCA: HER2 resistance to neratinib was associated with reduction in HER2 copy number and decreased ERBB2 S310F variant allele frequency in paired tumor/cfDNA analyses PMID:25526346
- Focus of the SUMMIT basket trial (NCT01953926): 141 patients with ERBB2-mutant (n=125) or ERBB3-mutant (n=16) advanced solid tumours across 21 cancer types; breast cancer met pre-specified efficacy endpoint (ORR8 32%, 95% CI 15-54%); bladder and colorectal cohorts showed lineage-based resistance; response jointly determined by tumour lineage and mutant allele PMID:29420467
Resistance mechanisms
- Not directly characterized in the corpus.
Cancer types (linked)
Sources
This page was processed by crosslinker on 2026-05-14. - PMID:25526346
This page was processed by crosslinker on 2026-05-14. - PMID:29420467
This page was processed by entity-page-writer on 2026-05-15.